Clinical trial DESTINY- Breast12
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Breast Cancer (DESTINY- Breast12)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3/4 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2020-005048-46 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04739761 |
| Last update |